Daiichi Sankyo US

As a master storyteller, Kim Wix, Executive Director of Corporate Communications has dedicated her career crafting powerful messages that instill a deep connection with her audiences. She emphasizes the power of authentic communication and how the "magic of words" can evoke real emotions. Her approach ensures that every aspect of communication creates a connection that can inspire, empower, and inform. Want to learn more about our approach to storytelling and how it helps us deliver innovative medicines to patients with unmet needs? 🎥 Watch the full video to discover the power of communicating with empathy and a human touch: https://bit.ly/4iqoMot    #PatientCentric #Storytelling #CorporateCommunications #DSProud #EmpathyInAction 

We are deeply honored to share that the World ADC Event Series has recognized Dr. Toshinori Agatsuma’s remarkable contributions to the field by naming the Long-Standing Contribution Recognition after him. This prestigious accolade celebrates his enduring impact and dedication to advancing antibody-drug conjugate (ADC) research and development. We express our deepest gratitude and look forward to the World ADC San Diego meeting in November where the first award in his name will be presented. Dr. Agatsuma’s legacy will continue to inspire and drive innovation in the ADC community for years to come. 🔗 Read more about this honor and Dr. Agatsuma’s achievements here: https://lnkd.in/eReC7tGW #WorldADC #DSProud

#BreakingNews: Today we announced positive topline overall survival results from the DESTINY-Gastric04 phase 3 trial in patients with HER2 positive metastatic #GastricCancer. https://bit.ly/41Eur52 Click the link for more information about these top line results. Gastric cancer is associated with a poor prognosis, making it one of the most challenging cancers to treat. At Daiichi Sankyo US we are committed to improving the standard of care across different lines of therapy in multiple types of cancer where high unmet need still exists.

Simona Ionescu's story is one of resilience, strength and hope. Diagnosed with Hodgkin’s lymphoma and breast cancer, she demonstrated that with determination and support, it's possible to overcome even the toughest battles.    Join us in celebrating the courage of the rare disease community in advocating for greater understanding, support and innovation in the treatment of rare diseases. Together, we can make a difference and bring hope to those affected by these complex conditions.  #RareDiseases #RareDiseaseDay

From molecular biology to human resources, Daiichi Sankyo US Chief People Officer, Simon King, has had a remarkable career journey. ▶ Watch to learn how his deep-seated passion for people helps him connect the right individuals at crucial moments—motivating them to do their best for the patients we serve.    Learn more about Simon’s craft in the full episode of “Where Craft Meets-People" on YouTube: https://bit.ly/3QpQxlp #WhereCraftMeets #oncology #cancer #innovation

Patients don't think like scientists - and they shouldn't have to.   Phrases like "antibody drug conjugates" can be overwhelming.  That’s where Gissoo DeCotiis’ craft comes in. She leads our team in translating highly complex texts, studies and information into easy-to-understand resources for patients wanting to know more about what the latest cancer research means for them. Learn more: https://bit.ly/4aiXFsL #PatientCare #WhereCraftMeets #PatientAdvocacy 

On #WorldCancerDay the global focus on addressing systemic challenges facing people impacted by cancer and the profound implication of a diagnosis is intensified.  The new phase of the Union for International Cancer Control (UICC) three-year focus for #WorldCancerDay, “United by Unique,” emphasizes a people-centered approach to cancer care, focusing on the unique stories and needs of each individual to achieve the best health outcomes for patients. This platform aligns deeply with Daiichi Sankyo US and our unwavering commitment to develop innovative medicines for the patients who need them most. It also reflects our philosophy of cultivating a workplace enriched by individuals, each with their own unique crafts that collectively helps us serve patients around the world. By recognizing and never losing sight that each person’s experiences and circumstances are unique the entire global oncology community can continue to advance science with the collective purpose of developing practice changing solutions for the patients of today and tomorrow.  This #WorldCancerDay I encourage my #LinkedIn network to support the Union For International Cancer Control (UICC) by sharing and discussing your unique stories. Through the practice of active listening, we can gain significantly greater knowledge and impact change more profoundly. https://bit.ly/MRWCD25   #UnitedByUnique #CancerAwareness #UICC #DaiichiSankyo #CancerResearch 

The new three-year theme for the Union for International Cancer Control (UICC) #WorldCancerDay, “United by Unique,” resonates deeply with all of us in the global oncology community. Each person is unique, and that’s why our approach to developing life-changing medicines for those affected by cancer cannot be one-size-fits-all. We are all unique, but not alone. We each experience triumphs and setbacks, tears of joy and moments of heartbreak. We dream of the future and, at times, struggle through life’s daily demands. While our journeys are individual, our shared resilience and determination help to create something remarkable — HOPE. World Cancer Day provides a powerful platform to remind us that, together, we must speak with one voice and work toward a common purpose, amplifying the mission of the UICC. Rallying around this day can be a catalyst for change, but it is our daily actions that truly demonstrate our commitment. At Daiichi Sankyo US, we are united by our uniqueness. Each of us brings a unique craft—skills we’ve mastered throughout our lives—that, when united, empower us to make a profound impact on the lives of those affected by cancer around the world. Through our united purpose, we have the unique responsibility of providing hope to so many. Each day, I am inspired by the hope and trust patients place in us, the compassion my teammates share, and the promise our innovative medicines hold for the patients of today and tomorrow. This #WorldCancerDay I encourage my #LinkedIn network to support the Union for International Cancer Control (UICC) mission by sharing your unique stories that inform, energize and inspire change. #YourStoryMatters #PeopleFirst #CancerAwareness #UICC #DaiichiSankyo #UnitedByOurUnique #CancerPrevention #CraftingHope

Check out how “Understanding ADCs,” an educational video co-created for US consumers with input from patients and our advocacy partners, came to life.    Informed patients are better equipped to participate in decision-making about their healthcare. That’s why Daiichi Sankyo partnered with patient advocates to fulfill a need for easily understandable information about antibody drug conjugates, or ADCs—a therapy option available for certain cancers.    🎥 Watch here: https://bit.ly/3WKTQqB #PatientAdvocacy  

Daiichi Sankyo today announced the appointment of Hiroyuki Okuzawa as its new global Chief Executive Officer (CEO), effective April 1, 2025. Mr. Okuzawa who currently serves as Representative Director, President, and COO, will succeed Sunao Manabe, who will continue to serve as Representative Director and Executive Chairperson. Join us in congratulating Mr. Okuzawa on his new appointment and recognizing the vision, exceptional leadership and unwavering commitment to patients and their families by Sunao Manabe through his esteemed career at Daiichi Sankyo. More information about Hiroyuki Okuzawa’s appointment and the strong foundation of innovation and compassion Sunao Manabe has led in the pivotal transformation of Daiichi Sankyo into a global company with competitive advantage in oncology can be found here: https://bit.ly/3EfXv9D